ATE139778T1 - Xanthinverbindungen - Google Patents

Xanthinverbindungen

Info

Publication number
ATE139778T1
ATE139778T1 AT90116791T AT90116791T ATE139778T1 AT E139778 T1 ATE139778 T1 AT E139778T1 AT 90116791 T AT90116791 T AT 90116791T AT 90116791 T AT90116791 T AT 90116791T AT E139778 T1 ATE139778 T1 AT E139778T1
Authority
AT
Austria
Prior art keywords
chem
effect
independently represents
renal
lower alkyl
Prior art date
Application number
AT90116791T
Other languages
English (en)
Inventor
Fumio Suzuki
Junichi Shimada
Akio Ishii
Tetsuji Ohno
Akira Karasawa
Kazuhiro Kubo
Hiromi Nonaka
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE139778T1 publication Critical patent/ATE139778T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/20—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
AT90116791T 1989-09-01 1990-08-31 Xanthinverbindungen ATE139778T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22664289 1989-09-01

Publications (1)

Publication Number Publication Date
ATE139778T1 true ATE139778T1 (de) 1996-07-15

Family

ID=16848383

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90116791T ATE139778T1 (de) 1989-09-01 1990-08-31 Xanthinverbindungen

Country Status (11)

Country Link
EP (1) EP0415456B1 (de)
JP (1) JPH06102662B2 (de)
AT (1) ATE139778T1 (de)
BR (1) BR1100762A (de)
CA (1) CA2024381C (de)
CY (1) CY2069B1 (de)
DE (1) DE69027562T2 (de)
DK (1) DK0415456T3 (de)
ES (1) ES2091212T3 (de)
GR (1) GR3020715T3 (de)
HK (1) HK1000600A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
CA2082325A1 (en) * 1991-11-08 1993-05-09 Fumio Suzuki Xanthine derivatives
EP0556778A3 (en) * 1992-02-17 1993-11-24 Kyowa Hakko Kogyo Kk Xanthine derivatives
US5342841A (en) * 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
TW252044B (de) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
DE4238367A1 (de) * 1992-11-13 1994-05-19 Boehringer Ingelheim Kg Diuretisches Mittel
WO1994016702A1 (en) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
EP0711772A4 (de) * 1994-05-17 1996-12-04 Kyowa Hakko Kogyo Kk Verfahren zur herstellung von xanthinederivaten
CA2206804C (en) 1994-12-13 2002-03-19 Euro-Celtique, S.A. Trisubstituted thioxanthines
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
ATE247116T1 (de) 1994-12-13 2003-08-15 Euro Celtique Sa Arylthioxanthine
WO1997004782A1 (fr) * 1995-07-26 1997-02-13 Kyowa Hakko Kogyo Co., Ltd. Dispersion solide ou preparation a dispersion solide de derives xanthine
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
AU7675498A (en) * 1997-06-16 1999-01-04 Kyowa Hakko Kogyo Co. Ltd. Preventive and remedy for drug-induced nephropathy
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0970696A1 (de) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Zusammensetzung von Schleifendiuretika und Adenosin A1 Rezeptor Antagonisten
CA2333947C (en) * 1998-06-01 2010-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds as adenosine a1 antagonist for male sterility
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
DK1230241T3 (da) * 1999-11-12 2007-06-04 Biogen Idec Inc Adenosinreceptorantagonister og fremgangsmåder til fremstilling og anvendelse af samme
CA2390496A1 (en) 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists
HUP0300927A2 (hu) 2000-04-26 2003-07-28 Eisai Co., Ltd. Új pirimidinszármazékok és ezeket tartalmazó defekációt elősegítő gyógyszerkészítmények
CZ20031513A3 (cs) * 2000-12-01 2003-09-17 Biogen, Inc. Kondenzované purinové deriváty jako antagonisty A1 adenosinového receptoru
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
BR0312137A (pt) * 2002-06-12 2005-04-05 Mcw Res Found Inc Processo de tratamento de dano de reperfusão de isquemia usando antagonistas de receptor de adenosina
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
ATE403656T1 (de) * 2003-05-06 2008-08-15 Cv Therapeutics Inc Xanthinderivate als a2b- adenosinrezeptorantagonisten
ES2440467T3 (es) * 2003-08-25 2014-01-29 Dogwood Pharmaceuticals, Inc. 8-heteroaril xantinas substituidas
JPWO2007069675A1 (ja) 2005-12-14 2009-05-28 協和発酵キリン株式会社 キサンチン誘導体の易吸収性経口製剤
GB0708258D0 (en) * 2007-04-27 2007-06-06 Katholleke Universiteit Leuven New anti-viral nulceoside analogs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
GB1201997A (en) * 1967-08-04 1970-08-12 Yissum Res Dev Co New substituted purines and purine derivatives
GB8618931D0 (en) * 1986-08-02 1986-09-10 Euro Celtique Sa 6-thioxanthines
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung

Also Published As

Publication number Publication date
CA2024381A1 (en) 1991-03-02
BR1100762A (pt) 2000-03-14
DK0415456T3 (da) 1996-07-29
CA2024381C (en) 1997-01-07
DE69027562D1 (de) 1996-08-01
JPH06102662B2 (ja) 1994-12-14
HK1000600A1 (en) 1998-04-09
EP0415456B1 (de) 1996-06-26
JPH03173889A (ja) 1991-07-29
CY2069B1 (en) 1998-09-11
ES2091212T3 (es) 1996-11-01
EP0415456A3 (en) 1991-05-29
DE69027562T2 (de) 1997-02-20
GR3020715T3 (en) 1996-11-30
EP0415456A2 (de) 1991-03-06

Similar Documents

Publication Publication Date Title
ATE139778T1 (de) Xanthinverbindungen
ATE138921T1 (de) Xanthinderivate
NO302755B1 (no) Morfinan-derivater
CA2124680A1 (en) Piperazine derivatives as 5-ht1a antagonists
EP0031567A3 (de) Tetrapeptidsemicarbazid-Derivate und deren Herstellung und Verwendung
FR2593504B1 (fr) Nouveaux derives de dihydrobenzofuranne - et de chromane - carboxamides, leurs procedes de preparation et leur utilisation comme neuroleptiques
DE3864707D1 (de) Benzoxazin-derivate und verfahren zu ihrer herstellung.
ATE71944T1 (de) Thiazolderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ATE148128T1 (de) Anthracyclinglycosid-derivate und verfahren zu ihrer herstellung
ES8702390A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,5-benzotiazepina
ES2003086A6 (es) Procedimiento de obtencion de tienoquinolicinsulfonamidas
ATE73795T1 (de) Thioformamid-derivate.
EP0347880A3 (de) Imidazo[2,1-b]benzothiazol-Verbindungen und diese enthaltende Antiulkus-Zubereitungen
ES2059451T3 (es) Derivados de naftotiazepina y su procedimiento de preparacion.
ES556048A0 (es) Un procedimiento para la preparacion de un derivado de tiazolidina.
ATE93524T1 (de) Mitomycinanaloge, verfahren zu ihrer herstellung und pharmazeutische zubereitungen.
AU4370489A (en) The use of oxidized polyamines, especially nn'-bis-(3- propionaldehyde)-1-4-diaminobutane (sperminedialdehyde) as immunosuppressive agents
NO885811L (no) Fremgangsmaate for fremstilling av 2-amino-tetrahydroisokinolinderivater.
MX9701841A (es) Derivados aminoheterociclicos como agentes antitromboticos o anticoagulantes.

Legal Events

Date Code Title Description
EEFA Change of the company name
EELA Cancelled due to lapse of time